Fig. 3

Oral administration with IRX4204 at peak disease (DPI 16) increases pro-myelinating gene expression in the spinal cord of EAE mice. (A–D) Expression of 2’,3’-Cyclic nucleotide 3’-phosphodiesterase (CNP; A), myelin-associated glycoprotein (MAG; B), myelin basic protein (MBP; C), and proteolipid protein (PLP; D) normalized relative to reference gene expression in mouse spinal cord. CNP, MAG, and PLP, expression increased in EAE mice treated with IRX4204 (12 mg/kg/day) compared to EAE mice treated with Veh (5 mL/kg/day) beginning at peak disease (n = 7, one-tailed Mann-Whitney U test, mean ± SEM; *p < 0.05, **p < 0.01)